Phase 1 Study of the PKMYT1 Inhibitor RP-6306 in Combination with Gemcitabine for the Treatment of Advanced Solid Tumors (MAGNETIC Study)
Study of RP-6306 in Combination with Gemcitabine (Chemotherapy) for Patients with Advanced Solid Tumors
Sponsor: Repare Therapeutics
Enrolling: Male and Female Patients
IRB Number: AAAT9785
U.S. Govt. ID: NCT05147272
Contact: Research Nurse Navigator: 212-342-5162 /
Additional Study Information: The purpose of this study is to learn how well RP-6306 (study drug) in combination with gemcitabine works to treat certain types of cancer. RP-6306 is a drug that is designed to stop certain cancer cells from growing by blocking a protein called PKMYT1. It is an investigational drug, which means that it has not been approved by any regulatory authorities, including the FDA. It is taken by mouth. RP-6306 (alone) has been given to patients in an ongoing study to understand how safe and effective it is. This is the first time RP-6306 is being given with gemcitabine to humans. Cancers include bladder cancer, breast cancer, colon and rectal cancer, kidney cancer, liver cancer, lung cancer, melanoma, pancreatic cancer, prostate cancer, and stomach cancer.
This study is closed
Ryan Moy, MD
Do You Qualify?
Do have you advanced solid tumors? Yes No
Are you able to swallow and retain oral medications? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator